Prime Medicine, Inc. (PRME)
- Sector
- Biotechnology
- Last price
- $3.32
- As of
Kresmion compiles this page from PRME's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Prime Medicine, Inc. (PRME): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
See the full PRME dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PRME on one page. Preview it with sample data, then open it live with a free account.
Preview the PRME dossierActive signals for PRME
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 8.6%, EPS $-0.24 vs $-0.2625 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +905% to PRME (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +732% to PRME (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 84% of PRME (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 53% of PRME (2026Q2)
FREE, NO ACCOUNT
Every signal on PRME, as it fires
You are seeing 5 of 8 signals recorded on PRME since 2026-05-17.
The five above landed across 2 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PRME (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 74168J101 · 2026Q2 | $7.6M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 74168J101 · 2026Q2 | $5.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 74168J101 · 2026Q2 | $2.4M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 74168J101 · 2026Q2 | $2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 74168J101 · 2026Q2 | $1.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 74168J101 · 2026Q2 | $433K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PRME
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PRME against its peers
PRME's operating margin of -4498.1% ranks in the 11th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | PRME | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.6M USD | 106M USD | 11 | 13 |
| Operating margin | -4498.1% | -59.1% | 11 | 13 |
| Net margin | -4342.4% | 0.7% | 11 | 13 |
| Return on equity | -166.4% | -39.4% | 13 | 19 |
| P / E | n/a | 14.7x | n/a | 5 |
| 1 year | -41.2% | -2.8% | 18 | 19 |
Peers (21): OLMA, WVE, ZVRA, AURA, CLYM, IRWD, PHAR, VSTM, STTK, MDXG, XOMA, SGMT, DBVT, CADL, FDMT, SLDB, NVCT, ACHV, GYRE, PHAT, CRMD. Left out: BLSM (no annual filing), IVA (period gap), ETRA (no annual filing), HELP (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (PRME: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PRME on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PRME for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.